To Get Full Access :

Ebglyss

Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Lebrikizumab-Lbkz
  • Innovator :

    ELI LILLY
  • Approval Date :

    13-Sep-24
  • Data Exclusivity Expiry :

    13-Sep-28
  • Market Exclusivity Expiry :

    13-Sep-36
  • Dosage Form :

    Prefilled Pen Subcutaneous Injection
  • Strength :

    250mg
  • Therapeutic Category :

    Immunomodulators
  • Revenue ($M) :

    79

Year-wise Projected Sales ($M) :

  • 2025 :

    423
  • 2026 :

    906
  • 2027 :

    1,278
  • 2028 :

    1,694
  • 2029 :

    2,153
  • 2030 :

    2,493
  • 2031 :

    2,819
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?